Ayala Pharmaceuticals (NASDAQ:ADXS) Research Coverage Started at StockNews.com

Analysts at StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXSGet Rating) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

About Ayala Pharmaceuticals

(Get Rating)

Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.

Featured Articles

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.